1 Supplemental data

Supplemental Table 1. Treatment capsule allocation and timing of administration.

Treatment	Delayed release capsule ¹ (1100h, T = 0)	Standard capsule ² (1130h, T = 30)			
Gastric	2x Vehicle control (125 mg oil ³ /capsule)	2x Amarasate (250 mg extract ⁴ /capsule)			
Duodenum	2x Amarasate (250 mg extract ⁴ /capsule)	2x Vehicle control (125 mg oil ³ /capsule)			
Placebo	2x Vehicle control (125 mg oil ³ /capsule)	2x Vehicle control (125 mg oil ³ /capsule)			

¹Delayed-release HPMC capsules (size 0, DRCaps[™], Capsugel); ²Standard HPMC capsules (size 0, VCaps[™], Capsugel); ³Canola oil; ⁴Amarasate[®], a bitter supercritical CO₂ extract of hops (*Humulus lupulus*).

Supplemental Table 2. Nutritional composition of the standard breakfast and *ad libitum* lunch and
snack meals¹.

	Weight (g)	Energy (kJ)	CHO (g)	CHO en%	Fat (g)	Fat en%	Protein (g)	Protein en%
Standard breakfast (250	g serving,	2 MJ)						
Puffed rice cereal	50	815	43	88	0.6	3	3.7	8
Milk, low fat	120	232	5.8	40	1.7	27	4.2	31
White bread	55	550	23.7	72	1.3	9	5	15
Margarine, spread	10	240	0	0	6.5	100	0	0
Berry jam	15	170	9.7	95	0	1	0.1	1
Ad lib lunch: pasta & me	at sauce (2145 g serv	ving, 8.9 N	IJ)				
Pasta, spirals, boiled	981	5668	270	81	5.4	4	44	13
Meat sauce, beef and tomato	1164	3242	46	24	33	37	69	36
Ad lib snack: ham sandw	vich (348 g	serving, 3	.2 MJ)					
White bread	204	2051	88	72	5	9	19	15
Margarine, spread	24	626	0	0	17	100	0	0
Ham, sliced	120	528	2	7	6	43	16	50

¹Ad lib, *ad libitum*; CHO, carbohydrate; Prot, protein; En%, energy percentage.

Supplemental Table 3. Visual analogue scale questions and their left and right anchor statements used
to access subjective ratings of the factors appetite, vitality, gastrointestinal discomfort and meal
palatability.

Factors	Question	Left Anchor	Right Anchor		
Appetite					
Hunger	How hungry do you feel?	I am not hungry at all	I am as hungry as I'v ever been		
Fullness	How full do you feel?	I am not full at all	I am totally full		
Satiety	Satiety How satisfied do you feel?		I cannot eat another bite		
Prospective Consumption	How much do you think you can eat now?	Nothing at all	A large amount		
Thirst	How thirsty do you feel?	I'm not thirsty at all	I am as thirsty as I've ever been		
Vitality					
Energetic	How energetic do you feel?	I do not feel energetic at all	I am as energetic as I have ever been		
Relaxation	How relaxed do you feel?	I do not relaxed at all	I am as relaxed as I have ever been		
Gastrointestinal Dis	scomfort				
Urge to vomit	Do you have the urge to vomit?	Nothing at all	A large amount		
Nauseous	Do you feel sick or nauseous?	Not at all	Very nauseous		
Bloating	Do you feel bloated?	Not at all	A large amount		
Abdominal discomfort	Do you have abdominal cramp or discomfort?	Nothing at all	A large amount		
Heartburn	Do you have any heartburn?	Nothing at all	A large amount		
Meal palatability					
Pleasantness	How pleasant was the meal?	Not at all pleasant	As pleasant as I have ever tasted		
Visual Appeal	How did the meal look?	Bad	Good		
Smell	How did the meal smell?	Bad	Good		
Taste	How did the meal taste?	Bad	Good		
Aftertaste	Aftertaste How much aftertaste was there?		Much		
Overall Palatability	How appealing was the meal?		Good		

5	5	(/		5			
	Ghrelin (active) (pg/mL)	GIP (pg/mL)	GLP-1 (active) (pg/mL)	Insulin (pg/mL)	PP (pg/mL)	PYY (pg/mL)	CCK (pM)
Standard curve	13.7–10,000	1.4–1000	2.7–2000	137–	2.7–2000	13.7–10000	0.78–50
				100,000			
Min DC	13.6	0.7	1.4	58.9	1.8	11.4	0.63
Max DC	11956	2398	4595	231314	4094	6846	181
Interassay	5.3	4.7	8.1	3.9	4.4	4.9	9.2
%CV							
Intraassay	2.5	3.4	3.9	3.1	3.8	6.3	4.1
%CV							

Supplemental Table 4. Immunoassay quality control values for the Magpix multiplexed magnetic bead 22 assays1 and the Cholecystokinin (CCK) radioimmunoassay2.


23 ¹Plasma active ghrelin, active glucagon-like peptide-1 (GLP-1), total peptide YY (PYY), insulin, total glucose-

24 dependent insulinotropic polypeptide (GIP) and pancreatic polypeptide (PP) concentrations were measured using


25 a multiplexed magnetic bead assay (HMHMAG-34K; Merck-Millipore, Massachusetts USA). Cholecystokinin was 26 measured using a commercial radioimmunoassay kit (EURIA-CCK, Eurodiagnostica). Minimal detectable

27 concentration (Min DC), maximal detectable concentration (Max DC).


28



Supplemental Figure 1. HPLC UV chromatogram (A) of the supercritical CO₂ hops extract used in the formulation of the Amarasate® treatments. Peak identifications, retention time and relative concentration expressed as percentages are listed in the included table (B).




Supplemental Figure 2. CONSORT flow diagram showing the flow of participants through the process
of recruitment, randomization to the six possible treatment sequences, exclusions and data analysis.
Treatments are (A) duodenal and (B) gastric delivery of a hops extract or (C) placebo (vehicle control).
Figure is based on the recommendations of the CONSORT extension to randomized crossover trials
(105).






43 Supplemental Figure 3 VAS ratings of (A) energetic and (B) relaxed following administration of a 44 control (Placebo) or Amarasate® targeted to either the small intestine (Duodenal) or stomach (Gastric) 45 using delayed-release or standard capsules, respectively. Arrows indicate capsule administration; grey 46 bars indicate the time allowed for the 2 MJ fixed energy breakfast and the *ad libitum* lunch and snack. 47 Analysis was conducted using the mixed procedure (SAS 9.4) with treatment, time, visit number and 48 treatment order as factors. A significant effect of treatment (p < 0.05) was observed for energetic. Fisher's 49 LSD *post hoc* pairwise comparisons: gastric v placebo (*p < 0.05); duodenal v placebo (p < 0.05, $^{p} < 0.05$); duodenal v placebo (p < 0.05, $^{p} < 0.05$); duodenal v placebo (p < 0.05, $^{p} < 0.05$); duodenal v placebo (p < 0.05); duodenal v place 50 0.01, ^^^ p < 0.001). Histograms show effect of treatment on VAS AUC_{0.300 min} for each vitality scale from 51 0 to 300 min. Analysis was conducted using the mixed procedure (SAS 9.4) with treatment, visit number 52 and treatment order as factors. A significant effect of treatment was observed for energetic (p = 0.017), 53 with letters denoting significantly (p < 0.05) different means. Values are means ± SEM; n = 19. Ad lib, ad 54 libitum



Supplemental Figure 4 VAS ratings of (A) pleasantness, (B) visual appeal, (C) smell, (D) taste, (E) aftertaste, and (F) overall palatability obtained after the 2 MJ fixed energy breakfast (Breakfast) and the *ad libitum* lunch (*Ad lib* lunch) or snack (*Ad lib* snack). Treatments comprised administration of a vehicle control (Placebo) or Amarasate® targeted to either the small intestine (Duodenal) or stomach (Gastric) using delayed-release or standard capsules, respectively. Analysis was conducted using the mixed procedure (SAS 9.4) with treatment, visit number and meal (breakfast, *ad lib* lunch and *ad lib* snack) as factors. No significant effect of treatment was seen for any measure. Values are means ± SEM; n = 19. *Ad lib, ad libitum*.



68 69 70

Supplemental Figure 5 Effect of treatment on changes in mood state assessed using the Profile of Mood States (POMS) questionnaire subscales (A) Tension-Anxiety, (B) Depression-Dejection, (C) Anger-71 Hostility, (D) Vigor-Activity, (E) Fatigue-Inertia, (F) Confusion-Bewilderment, and the computed (G) 72 total mood disturbance. Participants were asked to rate "how are you feeling right now?". The 73 questionnaire was administered 1 h before (Pre, T = -60 min) receiving the treatment and repeated at T 74 = 270 min (Post). Treatments comprised administration of a vehicle control (Placebo) or Amarasate® 75 targeted to either the small intestine (Duodenal) or stomach (Gastric) using delayed-release or standard 76 capsules, respectively. Analysis was conducted using the mixed procedure (SAS 9.4) with treatment, 77 visit number and time (pre/post) as factors. A significant effect of treatment was observed for B and C 78 (p < 0.05) only. Letters denote significantly (p < 0.05) different means using Fisher's LSD *post hoc* pairwise 79 comparisons. Values are means ± SEM; n = 19.